<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Genfit Sa — News on 6ix</title>
    <link>https://6ix.com/company/genfit-sa-1</link>
    <description>Latest news and press releases for Genfit Sa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 25 May 2026 16:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/genfit-sa-1" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d53245beedb30cb6f6da6d.webp</url>
      <title>Genfit Sa</title>
      <link>https://6ix.com/company/genfit-sa-1</link>
    </image>
    <item>
      <title>GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-highlights-broad-scientific-and-strategic-presence-at-easl-congress-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-highlights-broad-scientific-and-strategic-presence-at-easl-congress-2026</guid>
      <pubDate>Mon, 25 May 2026 16:00:00 GMT</pubDate>
      <description>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 25, 2026 – GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today highlights its broad participation at EASL Congress 2026. This visibility reflects both its scientific momentum and its active involvement in the ACLF ecosystem, as well as its position at an inflection point in MASH, while also highlighting the continuo</description>
    </item>
    <item>
      <title>GENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory Documents</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-annual-combined-general-meeting-of-june-15-2026-availability-of-preparatory-documents</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-annual-combined-general-meeting-of-june-15-2026-availability-of-preparatory-documents</guid>
      <pubDate>Mon, 11 May 2026 17:00:00 GMT</pubDate>
      <description>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 11, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the May 11, 2026 French legal announcements bulletin n°56 (Bulletin des Annonces Légales Obligatoires - BALO) the notice of the Combined Shareholders Meeting, which will be held on June 15, 2026, at 10:00 am (CET), at the F</description>
    </item>
    <item>
      <title>GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-receives-fda-orphan-drug-designation-for-ntz-for-the-treatment-of-aclf</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-receives-fda-orphan-drug-designation-for-ntz-for-the-treatment-of-aclf</guid>
      <pubDate>Mon, 09 Mar 2026 17:00:00 GMT</pubDate>
      <description>FDA grants Orphan Drug Designation (ODD) for NTZ for ACLF, a severe condition with no approved therapiesNTZ is being advanced in ACLF through its G1090N reformulation, designed to unlock its clinical potential for patients facing this life‑threatening conditionThis regulatory milestone follows favorable Phase 1 safety results and strong anti-inflammatory activity observed in ex vivo assays on samples from healthy volunteers and cirrhotic donors Lille (France), Cambridge (Massachusetts, United St</description>
    </item>
    <item>
      <title>GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-reports-fourth-quarter-2025-financial-information-and-provides-a-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-reports-fourth-quarter-2025-financial-information-and-provides-a-corporate-update</guid>
      <pubDate>Thu, 26 Feb 2026 17:00:00 GMT</pubDate>
      <description>Cash and cash equivalents totaled €101.1 million as of December 31, 2025Revenues amounted to €65.4 million as of December 31, 2025Ipsen’s strong performance with Iqirvo® in PBC (&gt;$200M net sales in year one) triggered GENFIT’s €17.0 million ($20.0 million) milestone, included in reported revenues, but not yet reflected in the cash positionACLF and CCA programs progressing according to plan Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 26, 2026 - GENFIT</description>
    </item>
    <item>
      <title>GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-to-receive-usdollar20m-milestone-after-ipsens-iqirvor-exceeds-the-usdollar200m-threshold-in-its-first-full-year-of-net-sales</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-to-receive-usdollar20m-milestone-after-ipsens-iqirvor-exceeds-the-usdollar200m-threshold-in-its-first-full-year-of-net-sales</guid>
      <pubDate>Thu, 12 Feb 2026 17:35:00 GMT</pubDate>
      <description>Ipsen reported US$88M of Iqirvo® net sales in PBC for 4Q25, bringing 2025 sales to US$208M, triggering the first commercial milestone payment to GENFIT ahead of schedule1Ipsen confirmed its commitment to launch a Phase 3 in PSC, creating a new avenue for potential future upside for GENFITGENFIT’s CCA Phase 1b study progressing as planned: New dose-escalation cohort fully enrolled with no dose-limiting toxicities reported at the 21-day timepoint Phase 1b data readout and recommended Phase 2 doses</description>
    </item>
    <item>
      <title>GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-half-year-report-of-liquidity-contract-with-credit-industriel-et-commercial</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-half-year-report-of-liquidity-contract-with-credit-industriel-et-commercial</guid>
      <pubDate>Tue, 13 Jan 2026 17:00:00 GMT</pubDate>
      <description>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 13, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31,</description>
    </item>
    <item>
      <title>GENFIT Announces 2026 Financial Calendar</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-announces-2026-financial-calendar</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-announces-2026-financial-calendar</guid>
      <pubDate>Wed, 07 Jan 2026 17:00:00 GMT</pubDate>
      <description>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026 - GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026. 2026 Financial Calendar February 26, 2026Publication of revenue and cash position at December 31, 2025April 2, 2026Publication of Full Year 2025 financial statements The 2025 Universal</description>
    </item>
    <item>
      <title>GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-favorable-phase-1-safety-profile-and-strong-anti-inflammatory-activity-for-aclf-lead-asset-g1090n</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-favorable-phase-1-safety-profile-and-strong-anti-inflammatory-activity-for-aclf-lead-asset-g1090n</guid>
      <pubDate>Tue, 06 Jan 2026 17:12:00 GMT</pubDate>
      <description>Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical evaluationCompelling anti-inflammatory activity of G1090N was evidenced through functional ex vivo assays on blood samples from study participants and cirrhotic donors, showing inhibition of pro-inflammatory pathwayFindings provide a solid foundation for advancing G1090N into Phase 2 proof-of-concept studies across the ACLF continuum Lille (France), Cambridge</description>
    </item>
    <item>
      <title>GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-gns561-shows-promising-antitumor-activity-in-combination-therapy</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-gns561-shows-promising-antitumor-activity-in-combination-therapy</guid>
      <pubDate>Wed, 10 Dec 2025 17:00:00 GMT</pubDate>
      <description>Highly encouraging early data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated cholangiocarcinoma (CCA), positioning this novel combination as a potential new therapeutic approach for difficult-to-treat cancers: No dose limiting toxicity reached to date, enabling recruitment of a third patient cohortGNS561 and MEKi combination demonstrated disease stabilization in all evaluable patients with evidence of tumor shrinkage in a subset</description>
    </item>
    <item>
      <title>GENFIT Announces Appointment of new Chief Medical Officer</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-announces-appointment-of-new-chief-medical-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-announces-appointment-of-new-chief-medical-officer</guid>
      <pubDate>Thu, 27 Nov 2025 17:00:00 GMT</pubDate>
      <description>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 27, 2025 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the appointment of Dr. Pejvack Motlagh, the new Chief Medical Officer of GENFIT. Member of the Executive Committee, Dr. Motlagh will oversee the strategy, direction, and execution of GENFIT’s clinical development plans and lead the Clinica</description>
    </item>
    <item>
      <title>GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-reports-third-quarter-2025-financial-information-and-provides-a-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-reports-third-quarter-2025-financial-information-and-provides-a-corporate-update</guid>
      <pubDate>Thu, 20 Nov 2025 17:10:00 GMT</pubDate>
      <description>Cash and cash equivalents totaled €119.0 million as of September 30, 2025€39.2 million in revenues for the nine months ended September 30, 2025, including the €26.5 million milestone payment following pricing and reimbursement approval of Iqirvo® (elafibranor) in three major European markets Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patient</description>
    </item>
    <item>
      <title>GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-announces-effectiveness-of-voluntary-delisting-of-american-depositary-shares-from-nasdaq-stock-market</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-announces-effectiveness-of-voluntary-delisting-of-american-depositary-shares-from-nasdaq-stock-market</guid>
      <pubDate>Thu, 20 Nov 2025 17:00:00 GMT</pubDate>
      <description>Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); November 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that the Company’s voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Global Select Market (“Nasdaq”) has become effective. Each ADS represents one ordinary share of the</description>
    </item>
    <item>
      <title>GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-enters-research-collaboration-with-everzom-to-advance-exosome-based-regenerative-technology-in-aclf</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-enters-research-collaboration-with-everzom-to-advance-exosome-based-regenerative-technology-in-aclf</guid>
      <pubDate>Mon, 10 Nov 2025 06:45:00 GMT</pubDate>
      <description>EVerZom’s investigational drug candidate EViv, developed to treat ACLF, using its proprietary exosome platform, represents a novel approach to regenerative therapies Pending successful in vivo proof-of-concept results, GENFIT has an exclusive option to take a license to drive EViv into clinical development Under this research collaboration, EVerZom will contribute exosome expertise with associated bioproduction platform, while GENFIT will spearhead preclinical evaluation of EViv Lille (France),</description>
    </item>
    <item>
      <title>GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-presents-promising-new-preclinical-data-on-ntzg1090n-for-the-treatment-of-aclf-at-the-liver-meetingr-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-presents-promising-new-preclinical-data-on-ntzg1090n-for-the-treatment-of-aclf-at-the-liver-meetingr-2025</guid>
      <pubDate>Mon, 10 Nov 2025 06:30:00 GMT</pubDate>
      <description>Preclinical studies demonstrated significant efficacy on systemic inflammation and organ function in ACLF disease modelsSafety data from Phase 1 on healthy volunteers and initial efficacy signals from ex-vivo functional assays expected by year-end 2025 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver d</description>
    </item>
    <item>
      <title>GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-announces-intention-to-voluntarily-delist-american-depositary-shares-from-the-nasdaq-global-select-market</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-announces-intention-to-voluntarily-delist-american-depositary-shares-from-the-nasdaq-global-select-market</guid>
      <pubDate>Thu, 30 Oct 2025 20:00:00 GMT</pubDate>
      <description>GENFIT’s decision to delist from Nasdaq reflects strategic intent to simplify corporate structure and improve operational efficiencyGENFIT remains listed on the regulated market of Euronext Paris as its primary trading market Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); October 30, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced it</description>
    </item>
    <item>
      <title>GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-announces-advances-across-its-aclf-pipeline-at-aasld-the-liver-meetingr-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-announces-advances-across-its-aclf-pipeline-at-aasld-the-liver-meetingr-2025</guid>
      <pubDate>Tue, 28 Oct 2025 21:10:00 GMT</pubDate>
      <description>Several posters and presentations featuring new data on three ACLF programs, including G1090N (NTZ reformulation) disease model data, new real-world data and biomarker insights in cirrhosisNew Iqirvo® PBC and PSC data to be presented by partner Ipsen, underscoring its potential in rare cholestatic liver diseases Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), October 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving</description>
    </item>
    <item>
      <title>GENFIT Reports First-Half 2025 Financial Results and  Provides Corporate Update</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-reports-first-half-2025-financial-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-reports-first-half-2025-financial-results-and-provides-corporate-update</guid>
      <pubDate>Mon, 22 Sep 2025 20:10:00 GMT</pubDate>
      <description>Cash and cash equivalents totaled €107.5 million as of June 30, 2025, excluding the €26.5 million milestone invoiced in May 2025 (received in July 2025) upon pricing and reimbursement approval of Iqirvo® (elafibranor) in three major European countries€33.5 million in revenues, including the €26.5 million milestone invoiced in May 2025Strong 1H25 sales trajectory reported by Ipsen for Iqirvo® in PBC in July, followed by U.S. market exit of key competitor in SeptemberFollowing discontinuation of t</description>
    </item>
    <item>
      <title>GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-announces-discontinuation-of-its-vs-01-program-in-aclf-vs-01-development-refocused-on-ucd</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-announces-discontinuation-of-its-vs-01-program-in-aclf-vs-01-development-refocused-on-ucd</guid>
      <pubDate>Fri, 19 Sep 2025 20:10:00 GMT</pubDate>
      <description>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 19, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its decision to discontinue its VS-01 program in ACLF (Acute-on-Chronic Liver Failure), and reprioritize the development of VS-01 on UCD (Urea Cycle Disorder). GENFIT’s decision follows the occurrence of a peritonitis case repo</description>
    </item>
    <item>
      <title>GENFIT: June 17, 2025 Combined Shareholders Meeting Results</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-june-17-2025-combined-shareholders-meeting-results</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-june-17-2025-combined-shareholders-meeting-results</guid>
      <pubDate>Tue, 17 Jun 2025 18:30:00 GMT</pubDate>
      <description>All resolutions recommended by the Board of Directors approved (quorum: 27.21%). Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 17, 2025. The quorum on first convening amounted to 27.21% and shareholders a</description>
    </item>
    <item>
      <title>GENFIT Reports First Quarter 2025 Financial Information</title>
      <link>https://6ix.com/company/genfit-sa-1/news/genfit-reports-first-quarter-2025-financial-information</link>
      <guid isPermaLink="true">https://6ix.com/company/genfit-sa-1/news/genfit-reports-first-quarter-2025-financial-information</guid>
      <pubDate>Thu, 22 May 2025 20:10:00 GMT</pubDate>
      <description>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of March 31, 2025 and revenues for the first three months of 2025.1 Cash position As of March 31, 2025, the Company’s cash and cash equivalents amounted to €129.5 million compared with €74.0 million as</description>
    </item>
  </channel>
</rss>